Quarterly ResultAug 5, 2026, 06:04 AM
Ultragenyx Q2 Revenue Up 28% to $214M; Net Loss Narrows to $92M
AI Summary
Ultragenyx Pharmaceutical Inc. reported a 28% increase in total revenues for the second quarter of 2026, reaching $214 million, with product sales growing 38% to $112 million. The company's net loss for the quarter narrowed to $92 million from $115 million in the prior year. However, for the six months ended June 30, 2026, the net loss increased to $277 million, and cash and cash equivalents significantly decreased to $125 million from $421 million at year-end 2025, reflecting increased cash used in operating activities.
Key Highlights
- Q2 2026 total revenues increased 28% to $214 million from $167 million year-over-year.
- Q2 2026 product sales rose 38% to $112 million, while royalty revenue grew 18.6% to $102 million.
- Net loss for Q2 2026 narrowed to $92 million, or $(0.90) per share, from $115 million, or $(1.17) per share.
- For the six months ended June 30, 2026, total revenues were $350 million, up from $306 million.
- Six-month net loss increased to $277 million, or $(2.73) per share, compared to $266 million, or $(2.73) per share.
- Cash and cash equivalents stood at $125 million as of June 30, 2026, down from $421 million at December 31, 2025.
- Net cash used in operating activities for the six months increased to $294 million from $275 million year-over-year.
- The company announced a restructuring plan in February 2026 to achieve anticipated savings.
Price Impact
More from RARE